Tyme Technologies

TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” -- -- Syros Announces 1-for- 10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the “Merger”). At Syros' special meeting, Syros' stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros' common stock to holders of TYME's common stock in connection with the Merger and to certain of Syros' investors in connection with a concurrent private investment in public equity (“PIPE”) financing.

Syros and Tyme Technologies Announce Stockholder Approval of Merger

BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Syros”) and “FOR” all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for September 15, 2022 at 11:00 a.m., Eastern Time.

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

NEW ORLEANS , July 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

TYME TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME

Syros Pharmaceuticals

Wilmington, Delaware--(Newsfile Corp. - July 6, 2022) - Rigrodsky Law, P.A. is investigating Tyme Technologies, Inc. ("Tyme") (NASDAQ: TYME) regarding possible breaches of fiduciary duties and other violations of law related to Tyme's agreement to be acquired by Syros Pharmaceuticals, Inc. ("Syros") (NASDAQ: SYRS). Under the terms of the agreement, Tyme's shareholders will receive approximately 0.4312 shares of Syros common stock for each share of Tyme common stock they own.To learn more about this investigation...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger

NEW YORK , July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS) in connection with the proposed merger of the Company with TYME Technologies, Inc. ("TYME") (NASDAQ: TYME).  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will continue to trade publicly on the Nasdaq under the ticker symbol "SYRS.

SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.

NEW YORK , July 5, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Tyme Technologies, Inc. (TYME), relating to its merger with Syros Pharmaceuticals, Inc. TYME shareholders are expected to receive 0.43 shares of Syros per share they own. Click here for more information: https://www.monteverdelaw.com/case/tyme-technologies-inc.

Investor Alert - The M&A Class Action Firm Announces an Investigation of Tyme Technologies, Inc. - TYME

MILWAUKEE , July 5, 2022 /PRNewswire/ -- Ademi LLP is investigating TYME (NASDAQ:TYME) for possible breaches of fiduciary duty and other violations of law in its transaction with Syros.  Click here to learn how to join the action: https://www.ademilaw.com/case/tyme-technologies-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether TYME Technologies, Inc. has obtained a Fair Price in its transaction with Syros

Endo International

Ra Medical Systems Inc

Titan Pharma

Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving

Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue.

TYME Technologies Shares Surge On Merger Agreement With Syros Pharma

CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives.

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

-- $84.0 million in cash and marketable securities as of March 31, 2022 -- -- $84.0 million in cash and marketable securities as of March 31, 2022 --

TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results

Tyme Technologies Inc. TYME, -5.56% , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a financial adviser and Faegre Drinker Biddle & Reath LLP as its legal adviser. The move comes after the Bedminster, New Jersey-based company had to discontinue a Phase 2/3 trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer after the trial sponsor terminated the study arm due to futility.

Tyme Technologies shares jump premarket on news board to explore strategic options

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value. The Company has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor.

TYME Technologies, Inc. Announces Exploration of Strategic Options

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors. Christine D. Baker Named to Board of Directors The Company is pleased to announce that Christine D. Baker has been appointed to TYME's Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in busi

TYME Technologies, Inc. Announces Changes to its Board of Directors

-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April 11, 1:30pm ET; abstract available online --

TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third fiscal quarter ended December 31, 2021. Third Fiscal Quarter 2022 Business and Recent Highlights: OASIS Breast Cancer Trial Patient enrollment in the Phase II OASIS breast trial continued during the third fiscal quarter 2022. The Company is collaborating wi

TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time:

TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

TYME Technologies Inc will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC).

Why Are Tyme Technologies Shares Staring At 52-Week Low

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in seco

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference as follows: Date: Monday, January 10, 2022   On Demand: 7:00AM ET   Webcast: https://journey.ct.events/view/8689e139-56fc-489f-a7ff-f6007

TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference

The stock price of Tyme Technologies Inc (NASDAQ: TYME) fell by 1.66% in the most recent trading session. This is why it happened.

Tyme Technologies Stock (TYME): Why The Price Fell

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections. The Company believes that TYME-19, a synthetic bile acid, may have differentiated mechanisms that could offer alternatives for COVID-19 infected patients who may not be served by current and emerging oral agents. Bile

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its abstract, Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results, has been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium,

TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

News for Tyme Technologies Stock (TYME)